Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Dec 17;117(14):2696-2698.
doi: 10.1093/cvr/cvab137.

Does the cardioprotective effect of Empagliflozin involve inhibition of the sodium-proton exchanger?

Elizabeth Murphy  1 , David A Eisner  2
Affiliations
Editorial

Does the cardioprotective effect of Empagliflozin involve inhibition of the sodium-proton exchanger?

Elizabeth Murphy et al. Cardiovasc Res. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
EMPA inhibition of NHE has been proposed to play a role in cardioprotective effects of EMPA that are independent of EMPA’s effect on plasma glucose. (A) Schematic of a cell showing NHE, sodium calcium exchange (NCX) and mitochondria. (B) Stimulation of NHE in ischaemia or heart failure is proposed to lead to an increase in cardiac intracellular Na+ and Ca2+, and these ionic alterations can alter cardiac signalling and function. (C) EMPA inhibition of NHE would block or ameliorate these ionic alterations. To test whether EMPA inhibits cardiac NHE studies were done using an NH4 prepulse to acidify cardiomyocytes. (D) Zuurbier et al. studied rabbit cardiomyocytes and found that EMPA inhibited the pH recovery. (E) In contrast, Chung et al. studied rat cardiomyocytes and found that EMPA did not block pH recovery.
See this image and copyright information in PMC

Comment on

References

    1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128. - PubMed
    1. Vaughan-Jones RD, Spitzer KW, Swietach P.. Intracellular pH regulation in heart. J Mol Cell Cardiol 2009;46:318–331. - PubMed
    1. Baartscheer A, Schumacher CA, Wust RC, Fiolet JW, Stienen GJ, Coronel R, Zuurbier CJ.. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia 2017;60:568–573. - PMC - PubMed
    1. Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, Jancev M, Hollmann MW, Weber NC, Coronel R, Zuurbier CJ.. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia 2018;61:722–726. - PMC - PubMed
    1. Trum M, Riechel J, Lebek S, Pabel S, Sossalla ST, Hirt S, Arzt M, Maier LS, Wagner S.. Empagliflozin inhibits Na+/H+ exchanger activity in human atrial cardiomyocytes. ESC Heart Fail 2020;7:4429–4437. - PMC - PubMed